‘In 2021, 1.1 billion people worldwide were living with mental disorders’
About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds.
By Aparna S. May 28, 2025: World Schizophrenia Day was observed recently to encourage society and mental health professionals to re-evaluate how we.
HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.
HQ Team February 27, 2025: The uniformity of brain folding in the mid-frontal area suggests a developmental trait common to people with schizophrenia,.
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
September 24, 2024: Teva Pharmaceuticals presented new research demonstrating effective strategies for switching adult patients with schizophrenia from Perseris to Uzedy (risperidone extended-release.
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com